Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AKRO Akero Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: AKRO
Price (delayed)
$39.85
Market cap
$3.17B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.75
Enterprise value
$2.87B
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein,
Highlights
AKRO's equity is up by 40% year-on-year
Akero Therapeutics's quick ratio has decreased by 35% YoY but it has increased by 13% QoQ
AKRO's net income has shrunk by 66% YoY and by 6% QoQ
AKRO's debt is up by 39% year-on-year
Key stats
What are the main financial stats of AKRO
Market
Valuations
Earnings
Shares outstanding
79.62M
Market cap
$3.17B
Enterprise value
$2.87B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.71
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$285.42M
Net income
-$252.06M
EBIT
-$247.39M
EBITDA
-$247.12M
Free cash flow
-$230.11M
Per share
Balance sheet
Liquidity
EPS
-$3.75
EPS diluted
-$3.75
Free cash flow per share
-$3.43
Book value per share
$10.75
Revenue per share
$0
TBVPS
$12.3
Total assets
$825.89M
Total liabilities
$75.77M
Debt
$35.83M
Equity
$750.11M
Working capital
$730.63M
Debt to equity
0.05
Current ratio
19.38
Quick ratio
18.69
Net debt/EBITDA
1.23
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.5%
Return on equity
-32.2%
Return on invested capital
-54.1%
Return on capital employed
-31.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKRO stock price
How has the Akero Therapeutics stock price performed over time
Intraday
-5.99%
1 week
-11.19%
1 month
6.66%
1 year
91.59%
YTD
43.24%
QTD
-1.56%
Financial performance
How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$285.42M
Net income
-$252.06M
Gross margin
N/A
Net margin
N/A
AKRO's net income has shrunk by 66% YoY and by 6% QoQ
Akero Therapeutics's operating income has plunged by 65% YoY and by 6% from the previous quarter
Price vs fundamentals
How does AKRO's price correlate with its fundamentals
Growth
What is Akero Therapeutics's growth rate over time
Valuation
What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
3.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has decreased by 30% YoY
The stock's P/B is 61% above its last 4 quarters average of 2.3 but 4.9% below its 5-year quarterly average of 3.9
AKRO's equity is up by 40% year-on-year
Efficiency
How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on equity has decreased by 8% YoY
The ROA has contracted by 8% YoY
Akero Therapeutics's return on invested capital has increased by 5% YoY
Dividends
What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKRO.
Financial health
How did Akero Therapeutics financials performed over time
The total liabilities has soared by 69% year-on-year but it is down by 4.4% since the previous quarter
The company's total assets rose by 42% YoY
AKRO's debt is 95% smaller than its equity
AKRO's equity is up by 40% year-on-year
AKRO's debt is up by 39% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.